TrialBMC musculoskeletal disorders2024

The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study.

Jinmei Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.